Pyxis Oncology, Inc. Stock Analysis & AI Score
Pyxis Oncology, Inc. (PYXS) has an ST Score of 34.8 (C-), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.67 price target (+162.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Pyxis Oncology, Inc. (PYXS) has an ST Score of 34.8 (C-), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Buy with a $7.67 price target (+162.7% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityF
All factor grades
- ForecastA
- MomentumA-
- ValuationC
- GrowthD
- Financial StrengthD-
- ProfitabilityF
- Piotroski2/9
Contact
PYXS stock: frequently asked questions
What is PYXS's ST Score?
Pyxis Oncology, Inc. (PYXS) has an ST Score of 34.8 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PYXS a buy, hold, or sell?
Analysts rate PYXS a Buy, with a price target of $7.67 (+162.7% vs the current price). Our ST Score grades it C- (34.8/100). The ST Score is a data-driven signal, not a recommendation.
What are PYXS's factor grades?
Valuation C, Profitability F, Financial Strength D-, Momentum A-, Growth D, Forecast A.
What is PYXS's valuation grade?
Pyxis Oncology, Inc. (PYXS) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PYXS's growth grade?
Pyxis Oncology, Inc. (PYXS) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PYXS's profitability grade?
Pyxis Oncology, Inc. (PYXS) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PYXS's financial strength grade?
Pyxis Oncology, Inc. (PYXS) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PYXS?
The average analyst price target for Pyxis Oncology, Inc. (PYXS) is $7.67 from 12 analysts, which is +162.7% versus the recent price of $2.92.
What is PYXS's Piotroski score?
Pyxis Oncology, Inc. (PYXS) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.